Delfi aims for a cheaper liquid biopsy
With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.
Freenome aims to take on the big beasts
Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.
